Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17682248 | 0.85 | HPGD (0.36) | HPGDTSHRALDH1A1ATM | |
| SCHEMBL16254145 | 0.82 | ALDH1A1 (0.43) | HPGDTSHRALDH1A1ATM | |
| SCHEMBL17682243 | 0.81 | ALDH1A1 (0.35) | HPGDTSHRALDH1A1 | |
| SCHEMBL16254138 | 0.77 | HPGD (0.32) | HPGDTSHR | |
| SCHEMBL17682184 | 0.76 | TSHR (0.31) | HPGDTSHR | |
| SCHEMBL16309384 | 0.75 | HPGD (0.33) | HPGDTSHR | |
| SCHEMBL16254156 | 0.72 | LMNA (0.46) | HPGDTSHRALDH1A1 | |
| SCHEMBL16309643 | 0.70 | HPGD (0.30) | HPGDTSHR | |
| SCHEMBL16309645 | 0.70 | KCNH2 (0.38) | HPGDTSHRALDH1A1CA1CA2 | |
| SCHEMBL1357811 | 0.70 | TSHR (0.38) | HPGDTSHRALDH1A1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160101414-A1 | HIGHLY Z-SELECTIVE AND ENANTIOSELECTIVE RING OPENING/CROSS METATHESIS CATALYZED BY A RESOLVED STEREOGENIC-AT-RU COMPLEX | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2016-04-14 | — | — | US | disclosed |
| WO-2014186631-A1 | HIGHLY Z-SELECTIVE AND ENANTIOSELECTIVE RING OPENING/CROSS METATHESIS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2014-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160101414-A1 | HIGHLY Z-SELECTIVE AND ENANTIOSELECTIVE RING OPENING/CROSS METATHESIS CATALYZED BY A RESOLVED STEREOGENIC-AT-RU COMPLEX | ZFR, ZDHHC7, ORC3 | HPGD 3713/4885TSHR 3394/4885ALDH1A1 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.